← Back to Search

Robotic Trainer

Robotic Training for Limited Mobility(RoWaCaWa Trial)

Led By Elizabeth G Condliffe, MD, PhD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to fit into Trexo robotic gait trainer (both leg length and weight)
Unable to walk independently due to pediatric onset, non-progressive central nervous system disorder or injury (ie. cerebral palsy or acquired brain injury)
Must not have
Screening 3 weeks
Treatment Varies
Follow Upassessed at enrollment (week 0), before robotic training period (~week 4), after robotic training period (~week 16), and 3-months post-training (~week 28).
Awards & highlights
No Placebo-Only Group

RoWaCaWa Trial Summary

This trial is designed to help children with nervous system disorders who have difficulty walking on their own. A robotic trainer is a device that helps with movement and rehabilitation. The study will assess the feasibility and impacts of delivering robotic gait training at home.

Eligible Conditions
  • Limited Mobility
  • Spina Bifida
  • Spinal Cord Injury
  • Cerebral Palsy
  • Traumatic Brain Injury

RoWaCaWa Trial Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You are the right size and weight to use the Trexo robotic gait trainer.
You cannot walk by yourself because of a brain disorder or injury that happened when you were a child.

RoWaCaWa Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed at enrollment (week 0), before robotic training period (~week 4), after robotic training period (~week 16), and 3-months post-training (~week 28).
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed at enrollment (week 0), before robotic training period (~week 4), after robotic training period (~week 16), and 3-months post-training (~week 28). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Canadian Occupational Performance Measures (COPM)
Early Clinical Assessment of Balance (ECAB)
Goal Attainment Scaling
+2 more
Secondary outcome measures
Bowel Function
Caregiver Priorities & Child Health Index of Life with Disabilities (CP-CHILD)
+13 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

RoWaCaWa Trial Design

1Treatment groups
Experimental Treatment
Group I: Robotic Training PeriodExperimental Treatment1 Intervention
Participants will engage in robot assisted gait training on at least 5 days/week for at least 30 minutes each day, for a total period of 12 weeks.

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
754 Previous Clinical Trials
1,086,913 Total Patients Enrolled
Elizabeth G Condliffe, MD, PhDPrincipal InvestigatorUniversity of Calgary

Media Library

Robotic Walking (Robotic Trainer) Clinical Trial Eligibility Overview. Trial Name: NCT05473676 — N/A
Limited Mobility Research Study Groups: Robotic Training Period
Limited Mobility Clinical Trial 2023: Robotic Walking Highlights & Side Effects. Trial Name: NCT05473676 — N/A
Robotic Walking (Robotic Trainer) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05473676 — N/A
Limited Mobility Patient Testimony for trial: Trial Name: NCT05473676 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there vacancies in this trial to which participants may apply?

"Affirmative. According to information on clinicaltrials.gov, the trial is currently seeking volunteers and was first published on July 4th 2022 with recent revisions made on August 8th 2022. The study requires 12 individuals at a single site of recruitment."

Answered by AI

What are the primary aims of this medical experiment?

"The primary measure of success for this trial is Training Frequency. Secondary outcomes being monitored include Bowel Function, Number of Participants Enrolled and Completed, as well as Voluntary Muscle Activity. All these metrics will be assessed at various stages such enrollment (Week 0), before Robotic Gait Training period (~Week 4), following Robotic Gait Training period (~Week 16), and at 3-months post-training (~Week 28)."

Answered by AI

What is the approximate sample size for this clinical trial?

"Affirmative. Records on the clinicaltrials website signify that this investigation, which originated on July 4th 2022, is actively seeking participants. Thus far 12 patients have been recruited from a single location."

Answered by AI

Who else is applying?

What state do they live in?
What site did they apply to?
Pediatric Onset of Neuromotor Impairments Lab, Alberta Children's Hospital
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?

Why did patients apply to this trial?

We are looking for new technologies to improve our sons ability to walk.
PatientReceived 1 prior treatment
~0 spots leftby Dec 2023